Explore LQM technology with Fernando Dominguez as we discuss its role in AI and quantum advancements in our latest episode.

Lexicon Pharmaceuticals said on Monday the U.S. Food and Drug Administration requires more time to review the company's ...

An advisory committee last year found that Zynquista’s benefit-risk profile in type 1 diabetes was unfavorable due to cases ...

Lexicon Pharmaceuticals ( NASDAQ: LXRX) said that the FDA has asked for additional time to review additional data for the ...

Have you ever felt shame from a false accusation? It happened to me, and it turned out to be a good thing in the end.

This review is based on a screening which took place at the 2025 Fantastic Fest Film Festival. Good Luck, Have Fun, Don't Die ...

That very Noughties phrase “watercooler TV” has almost dropped out of the lexicon in recent years. Shared viewing experiences ...

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete ...

It’s the return of a unique game series — and a developer — that had been all but dead for almost 20 years. But it’s not a ...

The rapid growth of nanomedical trials calls for a unified lexicon to support clinical translation and foster collaboration ...

The FDA said it would delay feedback on a diabetes drug developed by Lexicon previously expected by the end of the month, saying it needed more time to review data Lexicon submitted.

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable ...